Beta Drugs Limited (NSE:BETA)

Beta Drugs Statistics

Total Valuation

Beta Drugs has a market cap or net worth of INR 17.06 billion. The enterprise value is 17.29 billion.

Market Cap	17.06B
Enterprise Value	17.29B

Important Dates

The last earnings date was Tuesday, November 4, 2025.

Earnings Date	Nov 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Beta Drugs has 10.09 million shares outstanding. The number of shares has decreased by -22.61% in one year.

Current Share Class	10.09M
Shares Outstanding	10.09M
Shares Change (YoY)	-22.61%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	1.05%
Owned by Institutions (%)	n/a
Float	3.36M

Valuation Ratios

The trailing PE ratio is 31.51.

PE Ratio	31.51
Forward PE	n/a
PS Ratio	4.37
PB Ratio	7.72
P/TBV Ratio	8.06
P/FCF Ratio	n/a
P/OCF Ratio	67.72
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.58, with an EV/FCF ratio of -49.21.

EV / Earnings	41.27
EV / Sales	4.43
EV / EBITDA	21.58
EV / EBIT	26.00
EV / FCF	-49.21

Financial Position

The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.66.

Current Ratio	3.09
Quick Ratio	2.12
Debt / Equity	0.66
Debt / EBITDA	1.82
Debt / FCF	-4.15
Interest Coverage	5.61

Financial Efficiency

Return on equity (ROE) is 20.85% and return on invested capital (ROIC) is 14.67%.

Return on Equity (ROE)	20.85%
Return on Assets (ROA)	10.63%
Return on Invested Capital (ROIC)	14.67%
Return on Capital Employed (ROCE)	17.81%
Revenue Per Employee	9.78M
Profits Per Employee	1.05M
Employee Count	399
Asset Turnover	1.00
Inventory Turnover	3.65

Taxes

In the past 12 months, Beta Drugs has paid 143.84 million in taxes.

Income Tax	143.84M
Effective Tax Rate	25.56%

Stock Price Statistics

The stock price has decreased by -20.07% in the last 52 weeks. The beta is -0.35, so Beta Drugs's price volatility has been lower than the market average.

Beta (5Y)	-0.35
52-Week Price Change	-20.07%
50-Day Moving Average	1,813.64
200-Day Moving Average	1,786.36
Relative Strength Index (RSI)	35.86
Average Volume (20 Days)	3,801

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beta Drugs had revenue of INR 3.90 billion and earned 418.99 million in profits. Earnings per share was 53.63.

Revenue	3.90B
Gross Profit	1.57B
Operating Income	665.10M
Pretax Income	562.83M
Net Income	418.99M
EBITDA	801.43M
EBIT	665.10M
Earnings Per Share (EPS)	53.63

Balance Sheet

The company has 1.23 billion in cash and 1.46 billion in debt, giving a net cash position of -231.88 million or -22.97 per share.

Cash & Cash Equivalents	1.23B
Total Debt	1.46B
Net Cash	-231.88M
Net Cash Per Share	-22.97
Equity (Book Value)	2.21B
Book Value Per Share	437.84
Working Capital	2.39B

Cash Flow

In the last 12 months, operating cash flow was 251.92 million and capital expenditures -603.27 million, giving a free cash flow of -351.35 million.

Operating Cash Flow	251.92M
Capital Expenditures	-603.27M
Free Cash Flow	-351.35M
FCF Per Share	-34.81

Margins

Gross margin is 40.37%, with operating and profit margins of 17.05% and 10.74%.

Gross Margin	40.37%
Operating Margin	17.05%
Pretax Margin	14.43%
Profit Margin	10.74%
EBITDA Margin	20.54%
EBIT Margin	17.05%
FCF Margin	n/a

Dividends & Yields

Beta Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	22.61%
Shareholder Yield	22.61%
Earnings Yield	2.46%
FCF Yield	-2.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 26, 2025. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 26, 2025
Split Type	Forward
Split Ratio	1.05

Scores

Altman Z-Score	n/a
Piotroski F-Score	3